Choose Your Country or Region

Dacinostat (LAQ824)

Name: Dacinostat (LAQ824)
Brand: Selleck Chemicals
SKU: S1095
Rating: 5 (19 reviews)

Catalog No.S1095 Synonyms: NVP-LAQ824

For research use only.

Dacinostat (LAQ824, NVP-LAQ824) is a novel HDAC inhibitor with IC50 of 32 nM and is known to activate the p21 promoter.

CAS No. 404951-53-7

Selleck's Dacinostat (LAQ824) has been cited by 19 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Related Compound Libraries

Other HDAC Products

CAY10603^New

CAY10603 (BML-281) is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202)^New

Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683, Zolinza) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Entinostat (MS-275)

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Download Inhibitor Catalog

HDAC Signaling Pathway Map

Biological Activity

Description

Dacinostat (LAQ824, NVP-LAQ824) is a novel HDAC inhibitor with IC50 of 32 nM and is known to activate the p21 promoter.

Targets

HDAC ^[1]
(Cell-free assay)

32 nM

In vitro

LAQ824 activates the expression of the gene encoding the p21 cell cycle inhibitor by activating the p21 promoter with 50% of the maximal promoter activation (AC50) of 0.30 μM. LAQ824 inhibits the cell growth of both H1299, a non-small cell lung carcinoma line, and HCT116, a colon cancer cell line with IC50 of 0.15 μM and 0.01 μM, respectively, and the antiproliferative effect of LAQ824 is selective toward the tumor cell lines while inducing only growth arrest in normal fibroblasts. Furthermore, LAQ824 induces a dose-dependent increase of p21 protein in A549 cells and an increase in the hypophosphorylated state of the Rb tumor suppressor. ^[1] A recent study shows that LAQ824 induces chromatin changes at the level of the IL-10 gene promoter that lead to enhanced recruitment of the transcriptional repressors HDAC11 and PU.1 and inhibits IL-10 production in BALB/c murine macrophages. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

H1299	M1rabWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MWLJcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgTFEzQTliaIXtZY4hdHWwZzDjZZJkcW6xbXGgZ4VtdCCpcn;3eIgtKEmFNUC9NE4yPSEQvF2=	NWP3N\|NFOTR3MkG0NlI>
HCT116	NIjKdmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NGnETVdKdmirYnn0c5J6KGGldHn2bZR6KGGpYXnud5QhUEOWMUG2JIh2dWGwIHPvcI9vKGOnbHyg[5Jwf3SqLDDJR\|UxRTBwMEGg{txO	NUfPc3hlOTR3MkG0NlI>
HCT116	NHr1dm1EgXSxdH;4bYNqfHliYYPzZZk>			NHHWNmhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYomgUXRVKGG\|c3H5MEBKSzVyPUCuNFUh\|ryP	NYLZeZBrOTd7NEG2NlU>
human mammary epithelial cells	NF;rRo5EgXSxdH;4bYNqfHliYYPzZZk>			MoPSR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gcYFudWG{eTDldIl1cGWuaXHsJINmdGy\|IHL5JG1VXCCjc4PhfUwhUUN3ME2xJO69VQ>?	NUi3SWFGOTd7NEG2NlU>
HEK293 cells	M1XqOWZ2dmO2aX;uJIF{e2G7			M4rHeGlvcGmkaYTpc44hd2ZiSFTBR\|EhcW5iSFXLNlk{KGOnbHzzMEBKSzVyPUCuNFAzPiEQvF2=	Mn\zNVg{ODh3NkO=
HeLa cells	Mo[5SpVv[3Srb36gZZN{[Xl?	NWXqZpN2OC5\|IN88US=>	M4\5bVE3KGh?	NWPqToNjUW6qaXLpeIlwdiCxZjDISGFEPC2vZXTpZZRm\CC{ZYDy[ZN{cW:wIH;mJG1GTjJvZHXw[Y5l\W62IITyZY5{[3KrcITpc44hcW5iSHXMZUBk\WyuczDheEAxNjNidV2gZYZ1\XJiMU[gbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=>	MX[xO\|k2Pjl6OB?=
HCT116 cells	NFXySGRRem:uaX\ldoF1cW:wIHHzd4F6			MlG2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZpkhVVSVIHHzd4F6NCCLQ{WwQVAvODF\|IN88US=>	NHG0RmgzODJyNUO5OC=>
H1299 cells	MlPIVJJwdGmoZYLheIlwdiCjc4PhfS=>			NHPhNG5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFixNlk6KGOnbHzzJIJ6KE2WUzDhd5NigSxiSVO1NF0xNjF4MTFOwG0>	NVTCSm9XOjB{MEWzPVQ>
H460 cells	Mnf0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mn\OOFghcA>?	MXnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIOFYxKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTB;MD6wO{DPxE1?	NGjEO2YzOTB5M{G2NC=>
HCT116 cells	NH7UOm1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnP6OFghcA>?	NX\RVYIxT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWMUG2JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFnDOVA:OC5yMUig{txO	MkDINlExPzNzNkC=
CCRF-CEM cells	NUL3W5FlWHKxbHnm[ZJifGmxbjDhd5NigQ>?			MnXyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFQ2LGMWNGVSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5{NUGg{txO	M3vZZVIyPjJzOEiz
K562 cells	Mn7rVJJwdGmoZYLheIlwdiCjc4PhfS=>			NIDaWZJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFu1OlIh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvPTVizszN	Mmm3NlE3OjF6OEO=
MOLT4 cells	NGLHRVBRem:uaX\ldoF1cW:wIHHzd4F6			MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTGS0JINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlMyOSEQvF2=	MmDINlE3OjF6OEO=
SR cells	NXLoZpByWHKxbHnm[ZJifGmxbjDhd5NigQ>?			NULwRlN1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTVkBk\WyuczDifUBUWkJiYYPzZZktKEeLNUC9Nk46QSEQvF2=	MUGyNVYzOTh6Mx?=
A549 cells	MYjQdo9tcW[ncnH0bY9vKGG\|c3H5			NFn0b5dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVEvODlizszN	NEH1SFAzOTZ{MUi4Ny=>
EKVX cells	NW\uNnB5WHKxbHnm[ZJifGmxbjDhd5NigQ>?			M2HLT2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRVvWXEBk\WyuczDifUBUWkJiYYPzZZktKEeLNUC9NU44PSEQvF2=	M376W\|IyPjJzOEiz
HOP62 cells	NVfKUIhjWHKxbHnm[ZJifGmxbjDhd5NigQ>?			MlrjRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKT2C2NkBk\WyuczDifUBUWkJiYYPzZZktKEeLNUC9NE42ODJizszN	MojuNlE3OjF6OEO=
HOP92 cells	M3rxO3Bzd2yrZnXyZZRqd25iYYPzZZk>			MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiRUEmyJINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlE6QSEQvF2=	MXOyNVYzOTh6Mx?=
NCI-H226 cells	NGHwVFFRem:uaX\ldoF1cW:wIHHzd4F6			NFnPZ4lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOjJ4IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1zLkSxJO69VQ>?	MUSyNVYzOTh6Mx?=
NCI-H23 cells	Mn7sVJJwdGmoZYLheIlwdiCjc4PhfS=>			NEXiVZdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOjNiY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTFwNTFOwG0>	NUi1WYQ1OjF4MkG4PFM>
NCI-H322M cells	NVHlS5RiWHKxbHnm[ZJifGmxbjDhd5NigQ>?			Mn3IRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFMzOk1iY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTJwMk[g{txO	NG[1eWEzOTZ{MUi4Ny=>
NCI-H460 cells	MmjyVJJwdGmoZYLheIlwdiCjc4PhfS=>			NVf6WWY4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MDDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTB;MD63JO69VQ>?	NUD5PJBJOjF4MkG4PFM>
COLO205 cells	NH\XdoZRem:uaX\ldoF1cW:wIHHzd4F6			NUW5fHpCSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDU2xQOjB3IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1zLkC4JO69VQ>?	NE\NNGgzOTZ{MUi4Ny=>
HCT116 cells	NWPrS5Q2WHKxbHnm[ZJifGmxbjDhd5NigQ>?			NGfhU\|BCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5\|NEeg{txO	MonVNlE3OjF6OEO=
HCT15 cells	MojoVJJwdGmoZYLheIlwdiCjc4PhfS=>			M1yzeWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVUh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVIvODdizszN	NXvwd28{OjF4MkG4PFM>
HT-29 cells	M3HsSHBzd2yrZnXyZZRqd25iYYPzZZk>			M2eze2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGStNlkh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvPTZ4IN88US=>	NF;LWGMzOTZ{MUi4Ny=>
KM12 cells	NYrLepY5WHKxbHnm[ZJifGmxbjDhd5NigQ>?			NETVTmRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvNNVIh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVEvODRizszN	MV6yNVYzOTh6Mx?=
SW620 cells	NV;UWnBXWHKxbHnm[ZJifGmxbjDhd5NigQ>?			M1jBW2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2e2NlAh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvPDd6IN88US=>	Mn7hNlE3OjF6OEO=
SF268 cells	MUPQdo9tcW[ncnH0bY9vKGG\|c3H5			Mkn2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVRkK2PEBk\WyuczDifUBUWkJiYYPzZZktKEeLNUC9NU42OyEQvF2=	MXuyNVYzOTh6Mx?=
SF295 cells	NYXKUJprWHKxbHnm[ZJifGmxbjDhd5NigQ>?			NGO5bGZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPGNlk2KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjd2MzFOwG0>	NIPXVIwzOTZ{MUi4Ny=>
SF539 cells	M1XSZXBzd2yrZnXyZZRqd25iYYPzZZk>			NH\sfZVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPGOVM6KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjl4NTFOwG0>	MYmyNVYzOTh6Mx?=
SNB19 cells	MnrnVJJwdGmoZYLheIlwdiCjc4PhfS=>			MkXLRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVTlKxPUBk\WyuczDifUBUWkJiYYPzZZktKEeLNUC9NU42OyEQvF2=	M4TqOVIyPjJzOEiz
SNB75 cells	Mo\qVJJwdGmoZYLheIlwdiCjc4PhfS=>			MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOQQke1JINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlMyQCEQvF2=	MYSyNVYzOTh6Mx?=
U251 cells	M4D3VXBzd2yrZnXyZZRqd25iYYPzZZk>			NXXXNIdSSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVNlUyKGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjd5MzFOwG0>	MljGNlE3OjF6OEO=
LOXIMVI cells	MomwVJJwdGmoZYLheIlwdiCjc4PhfS=>			MWfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEyRWFnNWmkh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVEvODhizszN	MmrrNlE3OjF6OEO=
MALME-3M cells	NXv2fI9XWHKxbHnm[ZJifGmxbjDhd5NigQ>?			M4rqd2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVHMUWUuO01iY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTBwNE[xJO69VQ>?	MX6yNVYzOTh6Mx?=
M14 cells	MWLQdo9tcW[ncnH0bY9vKGG\|c3H5			NWPFVVhWSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNNVQh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvQDR7IN88US=>	NIDNR2ozOTZ{MUi4Ny=>
MDA-MB-435 cells	NHTifY5Rem:uaX\ldoF1cW:wIHHzd4F6			MkmyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuPDN3IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1yLkWzO{DPxE1?	MoP4NlE3OjF6OEO=
SK-MEL-28 cells	NU\zdHRyWHKxbHnm[ZJifGmxbjDhd5NigQ>?			MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONLV3FUE0zQCClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC57OUOg{txO	M3S5[FIyPjJzOEiz
SK-MEL-5 cells	MnzJVJJwdGmoZYLheIlwdiCjc4PhfS=>			NIrQb4dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLMW1GVC13IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1yLkK3NUDPxE1?	MY[yNVYzOTh6Mx?=
UACC257 cells	MXrQdo9tcW[ncnH0bY9vKGG\|c3H5			NF:wRWFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGXBR2MzPTdiY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTBwM{mzJO69VQ>?	NUjQVpBEOjF4MkG4PFM>
UACC62 cells	NXj5[I4xWHKxbHnm[ZJifGmxbjDhd5NigQ>?			MnP0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCXQVPDOlIh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvOzd7IN88US=>	MY[yNVYzOTh6Mx?=
IGROV1 cells	NFewT25Rem:uaX\ldoF1cW:wIHHzd4F6			M4n5fGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSVfSU3YyKGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjF6NzFOwG0>	Mn[5NlE3OjF6OEO=
OVCAR3 cells	M3G4cHBzd2yrZnXyZZRqd25iYYPzZZk>			NHrV[oZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF;WR2FTOyClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OS5zMTFOwG0>	MkmxNlE3OjF6OEO=
OVCAR4 cells	M2PYcnBzd2yrZnXyZZRqd25iYYPzZZk>			MV3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE:YQ1HSOEBk\WyuczDifUBUWkJiYYPzZZktKEeLNUC9N{4zOSEQvF2=	NIPnboEzOTZ{MUi4Ny=>
OVCAR5 cells	NIC0SFFRem:uaX\ldoF1cW:wIHHzd4F6			NFLoUVhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF;WR2FTPSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5{NjFOwG0>	NWnuXo5xOjF4MkG4PFM>
OVCAR8 cells	M3HPRXBzd2yrZnXyZZRqd25iYYPzZZk>			M2DodmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iT2\DRXI5KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjR3IN88US=>	NUO5PVJTOjF4MkG4PFM>
NCI/ADR-RES cells	NUnifWEyWHKxbHnm[ZJifGmxbjDhd5NigQ>?			M3eySmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJM2FFWi2URWOgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyPUCuNVgh\|ryP	Mk\WNlE3OjF6OEO=
SKOV3 cells	M3SxTnBzd2yrZnXyZZRqd25iYYPzZZk>			M2jDe2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1vPWlMh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvPTJ2IN88US=>	MkLTNlE3OjF6OEO=
786-0 cells	MkTjVJJwdGmoZYLheIlwdiCjc4PhfS=>			NFjOSFRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIEe4Ok0xKGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NF0zNjN6IN88US=>	NXn5[2JqOjF4MkG4PFM>
A498 cells	NWLlb41EWHKxbHnm[ZJifGmxbjDhd5NigQ>?			MoLTRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNEm4JINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3ME2xMlEyKM7:TR?=	MnvQNlE3OjF6OEO=
ACHN cells	NX3IfIVqWHKxbHnm[ZJifGmxbjDhd5NigQ>?			MlvxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDQ1jOJINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3ME2xMlEh\|ryP	MmXrNlE3OjF6OEO=
Caki1 cells	M2O0NnBzd2yrZnXyZZRqd25iYYPzZZk>			MmjPRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFYXvpNUBk\WyuczDifUBUWkJiYYPzZZktKEeLNUC9NE43OTlizszN	M{C3TVIyPjJzOEiz
SN12C cells	MkHFVJJwdGmoZYLheIlwdiCjc4PhfS=>			M4TDd2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU16xNmMh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVMvQTJizszN	NVruWmVrOjF4MkG4PFM>
TK10 cells	NVv6cFBlWHKxbHnm[ZJifGmxbjDhd5NigQ>?			NY\YTJVJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDUT\|ExKGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjR2NDFOwG0>	MUKyNVYzOTh6Mx?=
UO31 cells	NFvmd2hRem:uaX\ldoF1cW:wIHHzd4F6			NV\Tb2pQSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVU\|MyKGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjR3MjFOwG0>	NFHBdZIzOTZ{MUi4Ny=>
PC3 cells	Mk[wVJJwdGmoZYLheIlwdiCjc4PhfS=>			NU[yVnFXSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVIxKM7:TR?=	M3S3PVIyPjJzOEiz
DU145 cells	NYLYVJNsWHKxbHnm[ZJifGmxbjDhd5NigQ>?			MXjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3ME2yPU46KM7:TR?=	MXmyNVYzOTh6Mx?=
MCF7 cells	NXnzXlBPWHKxbHnm[ZJifGmxbjDhd5NigQ>?			MmP4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3ME22MlkyKM7:TR?=	Ml65NlE3OjF6OEO=
MDA-MB-231 cells	NE\IZXNRem:uaX\ldoF1cW:wIHHzd4F6			M{TGZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTB;M{GuO{DPxE1?	M4fPVlIyPjJzOEiz
Hs 578T cells	NWTEOGVVWHKxbHnm[ZJifGmxbjDhd5NigQ>?			MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEi\|IEW3PHQh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVUvQDJizszN	Mk\4NlE3OjF6OEO=
BT549 cells	NGjVbHVRem:uaX\ldoF1cW:wIHHzd4F6			MXnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEKWNUS5JINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3ME22MlA1KM7:TR?=	MYqyNVYzOTh6Mx?=
T47D cells	NGfnRmFRem:uaX\ldoF1cW:wIHHzd4F6			MUjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFR2N1SgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyPUK4Mlgh\|ryP	MnjkNlE3OjF6OEO=
MDA-MB-468 cells	MnO2VJJwdGmoZYLheIlwdiCjc4PhfS=>			MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk01PjhiY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTVwOEig{txO	NVTRWFl6OjF4MkG4PFM>
NCI-H226 cells	NIK5eoNEgXSxdH;4bYNqfHliYYPzZZk>			MlzZR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh{Mk[gZ4VtdHNuIFzDOVA:OjBizszN	NWHtfGZVOjF4MkG4PFM>
KM12 cells	NH;hfHREgXSxdH;4bYNqfHliYYPzZZk>			NVHnUpc4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU01zMjDj[YxteyxiTFO1NF0zQS57IN88US=>	NEL4eWMzOTZ{MUi4Ny=>
SF295 cells	NIq1U2lEgXSxdH;4bYNqfHliYYPzZZk>			NWKxWpVLS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0Z{OUWgZ4VtdHNuIFzDOVA:Pi57MTFOwG0>	NXzqd3ZzOjF4MkG4PFM>
SNB19 cells	NIP0cWNEgXSxdH;4bYNqfHliYYPzZZk>			NWXHUXh7S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW06EMUmgZ4VtdHNuIFzDOVA:OzFwNzFOwG0>	NGfOdFYzOTZ{MUi4Ny=>
U251 cells	NIDVPW1EgXSxdH;4bYNqfHliYYPzZZk>			MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDVNlUyKGOnbHzzMEBNSzVyPUWuPFIh\|ryP	MVGyNVYzOTh6Mx?=
LOXIMVI cells	MUHDfZRwfG:6aXPpeJkh[XO\|YYm=			MV3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMU3hKVV[LIHPlcIx{NCCOQ{WwQVYvODRizszN	Moj1NlE3OjF6OEO=
MDA-MB-435 cells	NEPsO4lEgXSxdH;4bYNqfHliYYPzZZk>			MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEO1JINmdGy\|LDDMR\|UxRTJ6Lkig{txO	NETu[JgzOTZ{MUi4Ny=>
SK-MEL-28 cells	M1THTGN6fG:2b4jpZ4l1gSCjc4PhfS=>			NITONHJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUy2PRVytNlgh[2WubIOsJGxEPTB;M{GuPUDPxE1?	Mnn1NlE3OjF6OEO=
SK-MEL-5 cells	MkX6R5l1d3SxeHnjbZR6KGG\|c3H5			NGDCc4pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUy2PRVytOUBk\WyuczygUGM2OD12LkCyJO69VQ>?	M4f6bVIyPjJzOEiz
UACC257 cells	MX7DfZRwfG:6aXPpeJkh[XO\|YYm=			M4HVWmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHVCS0N{NUegZ4VtdHNuIFzDOVA:PDRwODFOwG0>	MX:yNVYzOTh6Mx?=
UACC62 cells	M{Tre2N6fG:2b4jpZ4l1gSCjc4PhfS=>			MnfuR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWWFESzZ{IHPlcIx{NCCOQ{WwQVYvOzlizszN	NWnkb\|N[OjF4MkG4PFM>
IGROV1 cells	M1TGXWN6fG:2b4jpZ4l1gSCjc4PhfS=>			MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDJS3JQXjFiY3XscJMtKEyFNUC9OFgvQSEQvF2=	NH3mfWczOTZ{MUi4Ny=>
OVCAR5 cells	NF\LWJVEgXSxdH;4bYNqfHliYYPzZZk>			MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDPWmNCWjViY3XscJMtKEyFNUC9N\|gvQSEQvF2=	MYCyNVYzOTh6Mx?=
SKOV3 cells	NYqxVGJtS3m2b4TvfIlkcXS7IHHzd4F6			MV3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT29XOyClZXzsd{whVEN3ME2yPE42KM7:TR?=	MXKyNVYzOTh6Mx?=
A498 cells	M1y3PWN6fG:2b4jpZ4l1gSCjc4PhfS=>			Mnr1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ6QCClZXzsd{whVEN3ME21Mlg5KM7:TR?=	M{Ox[FIyPjJzOEiz
Caki1 cells	MUPDfZRwfG:6aXPpeJkh[XO\|YYm=			MVXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDZYtqOSClZXzsd{whVEN3ME21Mlc6KM7:TR?=	MkPnNlE3OjF6OEO=
HCT116 cells	NIPHVWVRem:uaX\ldoF1cW:wIHHzd4F6			MnLORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOsJGlEPTB;MD6wNVkh\|ryP	Mn:3NlE4PDJ2OU[=
HCT116 cells	M{n4UXBzd2yrZnXyZZRqd25iYYPzZZk>			NGjKT\|BCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdixiSVO1NF0xNjBzOTFOwG0>	MXeyNVY2ODJ{MR?=
H1299 cells	MVzQdo9tcW[ncnH0bY9vKGG\|c3H5			MXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEhzMkm5JINmdGy\|LDDJR\|UxRTBwMTFOwG0>	MUGyNVY2ODJ{MR?=
HCT116 cells	NYHoR5k4WHKxbHnm[ZJifGmxbjDhd5NigQ>?			NW\4RZFCUW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4SgTGNVOTF4IHPlcIx{KHC{b3zp[oVz[XSrb36sJGlEPTB;MD6wNUDPxE1?	NUL4U5JQOTR4MUOzNVI>
RPMI8226 cells	NYHYRWVHWHKxbHnm[ZJifGmxbjDhd5NigQ>?			NH7JU2pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGLQUWk5OjJ4IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1yLkWyN{DPxE1?	NGTt[HYzOTZ{MUi4Ny=>
CHO cells	NEfLRphHfW6ldHnvckBie3OjeR?=			NGf3fYlKdmirYnn0bY9vKG:oIHj1cYFvKEWURzDlfJBz\XO\|ZXSgbY4hS0iRIHPlcIx{KGK7IHH1eI9u[XSnZDDwZZRkcCClbHHtdEBmdGWldILvdIh6e2mxbH;nfUBie3OjeTygTWM2OD1zMj6yJO69VQ>?	NHGxXVczODJyNUO5OC=>
HL-60(TB) cells	MV;Qdo9tcW[ncnH0bY9vKGG\|c3H5			M{LUdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFytOlApXEJrIHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1yLkK0PUDPxE1?	MXOyNVYzOTh6Mx?=
RXF393 cells	NXjZT4VnWHKxbHnm[ZJifGmxbjDhd5NigQ>?			MmTBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCUWF[zPVMh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODFizszN	MkPBNlE3OjF6OEO=
RXF393 cells	NITJeXNEgXSxdH;4bYNqfHliYYPzZZk>			NIfURWhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBTYEZ\|OUOgZ4VtdHNuIFzDOVA:OTVwMzFOwG0>	MmPqNlE3OjF6OEO=

Click to View More Cell Line Experimental Data

In vivo

In HCT116 and human colon tumor xenografts in nude mice, LAQ824 treatment at 100 mg/kg produces the inhibitory effects on tumor growth in a dose-dependent mode without general cytotoxicity. ^[1]

Protocol (from reference)

Kinase Assay:^[1]	In Vitro Histone Deacetylase Assay: HDAC enzymes are partially purified from H1299 cell lysate by ion exchange chromatography using the Q Sepharose Fast Flow column. Enzyme complexes are collected from 500 mg of total cell lysate by immunoprecipitation with cdk2 polyclonal antibody or cdk1/cdc2 monoclonal antibody. Immunoprecipitates are resuspended in kinase buffer (50 mM Hepes, pH 8, 10 mM MgCl₂, 2.5 mM EDTA, 1 mM dithiothreitol, 20 mM ATP, 10 mM β-glycerophosphate, 0.1 mM NaVO₄, 1 mM sodium fluoride, 50 mM ATP, 10 μCi of [γ-³²P]ATP) along with 1 μg of pRb recombinant protein substrate (cdk2) or 10 mL of H1 histone mixture containing 20 μg of substrate (cdc2). Phosphorylated Rb and H1 histone are resolved by electrophoresis and quantitated using a PhosphorImager.
Cell Research:^[1]	Cell lines: H1299, HCT116, DU145, PC3 and MDA435 cells Concentrations: 0-10 μM Incubation Time: 48 hours Method: Cell proliferation is measured using an adaptation of published procedures (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfonyl)-2H-tetrazolium assay). The cells are seeded in 12-well dishes and cultured in RPMI 1640 containing 10% FBS. The cells are cultured in the presence of various concentrations of TSA (up to 1,000 ng/mL). To examine the growth inhibition by TSA, viable cell numbers are determined by trypan blue dye exclusion, counted in a Nesbauer-type hemocytometer for 0 hour, 24 hours, and 48 hours. The same amount of ethanol is added to the RPMI 1640 medium as the control experiment. All experiments are performed in duplicate and repeated 3 times The average background value (treatment with medium alone) is subtracted from each experimental well; triplicate values are averaged for each compound dilution. The following formulas are used to calculate the percentage of growth: If X0, %Growth=(X-T₀)/T₀100; If X>T₀, %Growth=(X-T₀)/(GC-T₀)100. where T₀ is the average value of T₀ − background, GC is the average value of untreated cells (in triplicate) − background, and X is the average value of compound-treated cells (in triplicate)-background. The “% Growth” is plotted against compound concentration and used to calculate the IC50 using the linear regression techniques between data points to predict the concentration of compounds at 50% inhibition.
Animal Research:^[1]	Animal Models: HCT116 cells is injected s.c. into the right axillary (lateral) region of outbred athymic (nu/nu) female mice. Dosages: ≤100 mg/kg Administration: Administered via i.v.

References

Solubility (25°C)

In vitro


In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O For best results, use promptly after mixing. Click to purchase: PEG300 Tween 80	15 mg/mL

Chemical Information

Molecular Weight	379.459
Formula	C₂₂H₂₅N₃O₃
CAS No.	404951-53-7
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	C1=CC=C2C(=C1)C(=CN2)CCN(CCO)CC3=CC=C(C=C3)C=CC(=O)NO

Download Dacinostat (LAQ824) SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):